#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should understand that terpenes like camphene contribute to cannabis’s pharmacological effects beyond THC and CBD, potentially influencing therapeutic outcomes and side effect profiles for patients. Knowledge of terpene composition enables more informed counseling about product selection and expected effects, improving patient safety and treatment efficacy. As cannabis products become increasingly standardized and labeled, clinicians can educate patients that terpene profiles matter for personalized medicine approaches to pain, anxiety, and other conditions.
This article highlights camphene, a minor terpene found in cannabis and common culinary and aromatic plants, which contributes to the plant’s aroma and sensory profile. Camphene belongs to the class of volatile organic compounds that, alongside cannabinoids, may influence the overall pharmacological effects and user experience of cannabis products through entourage effects. While research on camphene’s specific therapeutic properties remains limited, its presence in cannabis strains and other botanicals suggests potential contributions to anti-inflammatory, analgesic, or antimicrobial effects that warrant further investigation. Understanding the terpene composition of cannabis products is increasingly relevant for clinicians counseling patients about strain selection and expected effects, particularly as consumers seek products with specific aromatic and therapeutic profiles. Clinicians should remain aware that terpene profiles vary significantly between products and growing methods, which may influence both therapeutic outcomes and adverse effects in their patients.
“Terpenes like camphene are certainly present in cannabis and contribute to its sensory profile, but we’re still in early stages of understanding what clinically meaningful effects they have in humans. The anecdotal reports are intriguing, but I’d want to see rigorous peer-reviewed evidence before advising patients that specific terpenes provide particular therapeutic benefits.”
💊 While terpene profiling of cannabis products has generated considerable consumer and industry interest, the clinical evidence supporting specific therapeutic effects of individual terpenes like camphene remains limited and largely preclinical. The presence of terpenes in cannabis alongside cannabinoids complicates our ability to isolate their independent contributions to clinical outcomes, and claims about entourage effects, though plausible, lack robust controlled trials in human subjects. Additionally, the sensory appeal of terpene profiles may drive marketing claims that outpace scientific support, creating a disconnect between what consumers perceive as beneficial and what evidence actually demonstrates. Clinicians should remain cautious about endorsing specific terpene-based products as having particular therapeutic properties until higher-quality evidence emerges, while acknowledging that terpene composition may influence the overall pharmacological experience for patients in ways we do not yet fully understand.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
